ETIRINOTECAN PEGOL WAS GRANTED FAST TRACK BY THE FDA FOR METASTATIC BREAST CANCER REFRACTORY TO TAXANE, ANTHRACYCLINES AND XELODA.
This is the same setting indicated for Ixabepilone (Ixempra) and other Microtubule disrupting agents.
E. Pegol has anti topoIsomerase I activity.  reportedly designed using Nectar's polymer conjugate technology.  Call BEACON III to enroll patients.

As a topo-Isomerase inhibitor, I wonder if Bcl-2 status of patients would be critical in interpreting results?
will see if Researcher are looking at this as way to establish refractoriness?